124 related articles for article (PubMed ID: 12558787)
1. Hepatitis G virus in clotting factor concentrates.
Alonso-Rubiano E; Gerber M; Friedman P; Hodges S; Leissinger C
Haemophilia; 2003 Jan; 9(1):110-5. PubMed ID: 12558787
[TBL] [Abstract][Full Text] [Related]
2. GB virus C/hepatitis G virus infection in HIV infected patients with haemophilia despite treatment with virus inactivated clotting factor concentrates.
Woelfle J; Berg T; Bialek R; Keller KM; Effenberger W; Wagner N
Arch Dis Child; 1999 May; 80(5):429-32. PubMed ID: 10208947
[TBL] [Abstract][Full Text] [Related]
3. Comparison of GB virus C, HIV, and HCV infection markers in hemophiliacs exposed to non-inactivated or inactivated factor concentrates.
Kupfer B; Ruf T; Matz B; Nattermann J; Spengler U; Rockstroh JK; Brackmann HH; Blümel J; Tacke M; Kaiser R
J Clin Virol; 2005 Sep; 34(1):42-7. PubMed ID: 16087123
[TBL] [Abstract][Full Text] [Related]
4. Virus inactivation and prevalence of GBV-C in haemophiliacs.
Uhle C; Zimmermann R; Goeser T; Seelig R
Br J Haematol; 1997 Dec; 99(4):837-8. PubMed ID: 9432030
[TBL] [Abstract][Full Text] [Related]
5. Reconstruction of the historic time course of blood-borne virus contamination of clotting factor concentrates, 1974-1992.
McClure CP; Kean K; Reid K; Mayne R; Fu MX; Rajendra P; Gates S; Breuer J; Harvala H; Golubchik T; Tarr AW; Irving WL; Makris M; Simmonds P
J Med Virol; 2024 Jul; 96(7):e29774. PubMed ID: 38953434
[TBL] [Abstract][Full Text] [Related]
6. Infection with hepatitis G virus among recipients of plasma products.
Jarvis LM; Davidson F; Hanley JP; Yap PL; Ludlam CA; Simmonds P
Lancet; 1996 Nov; 348(9038):1352-5. PubMed ID: 8918279
[TBL] [Abstract][Full Text] [Related]
7. Detection of GB virus C/hepatitis G virus in semen and saliva of HIV type-1 infected men.
Bourlet T; Berthelot P; Grattard F; Genin C; Lucht FR; Pozzetto B
Clin Microbiol Infect; 2002 Jun; 8(6):352-7. PubMed ID: 12084103
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
Mannucci PM
Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
[TBL] [Abstract][Full Text] [Related]
9. Pathogen safety of plasma-derived products - Haemate P/Humate-P.
Gröner A
Haemophilia; 2008 Nov; 14 Suppl 5(Suppl 5):54-71. PubMed ID: 18786011
[TBL] [Abstract][Full Text] [Related]
10. [GBV-C/HGV and TTV infection markers in Polish blood donors and haemophilia patients].
Grabarczyk P; Brojer E; Windyga J; łopaciuk S; Klukowska A; Mikulska M
Przegl Epidemiol; 2006; 60(3):581-8. PubMed ID: 17249183
[TBL] [Abstract][Full Text] [Related]
11. Reduced mother-to-child transmission of HIV associated with infant but not maternal GB virus C infection.
Supapol WB; Remis RS; Raboud J; Millson M; Tappero J; Kaul R; Kulkarni P; McConnell MS; Mock PA; Culnane M; McNicholl J; Roongpisuthipong A; Chotpitayasunondh T; Shaffer N; Butera S
J Infect Dis; 2008 May; 197(10):1369-77. PubMed ID: 18419578
[TBL] [Abstract][Full Text] [Related]
12. Recently discovered blood-borne viruses.
Mushahwar IK; Erker JE; Dille BJ; Desai SM
Forum (Genova); 2001; 11(2):98-122. PubMed ID: 11948357
[TBL] [Abstract][Full Text] [Related]
13. [Investigation of hepatitis G virus prevalence in hemodialysis patients and blood donors in Denizli, Turkey].
Hanci SY; Cevahir N; Kaleli I; Hanci V
Mikrobiyol Bul; 2008 Oct; 42(4):617-25. PubMed ID: 19149083
[TBL] [Abstract][Full Text] [Related]
14. Molecular investigation of GB virus C RNA in hemodialysis and thalassemics patients from Brazil.
Watanabe MA; Milanezi CM; Silva WA; de Lucena Angulo I; Santis G; Kashima S; da Costa JA; Neto MM; Covas DT
Ren Fail; 2003 Jan; 25(1):67-75. PubMed ID: 12617334
[TBL] [Abstract][Full Text] [Related]
15. Clinical studies with treated clotting factor concentrates.
Colombo M; Mannucci PM
Dev Biol Stand; 1987; 67():333-6. PubMed ID: 3038639
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of GB virus type C/hepatitis G virus RNA and of anti-E2 in individuals at high or low risk for blood-borne or sexually transmitted viruses: evidence of sexual and parenteral transmission.
Lefrère JJ; Roudot-Thoraval F; Morand-Joubert L; Brossard Y; Parnet-Mathieu F; Mariotti M; Agis F; Rouet G; Lerable J; Lefèvre G; Girot R; Loiseau P
Transfusion; 1999 Jan; 39(1):83-94. PubMed ID: 9920171
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and clinical significance of HGV/GBV-C infection in patients with chronic hepatitis B or C.
Yang JF; Dai CY; Chuang WL; Lin WY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
Jpn J Infect Dis; 2006 Feb; 59(1):25-30. PubMed ID: 16495630
[TBL] [Abstract][Full Text] [Related]
18. GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype.
Schwarze-Zander C; Blackard JT; Zheng H; Addo MM; Lin W; Robbins GK; Sherman KE; Zdunek D; Hess G; Chung RT;
J Infect Dis; 2006 Aug; 194(4):410-9. PubMed ID: 16845623
[TBL] [Abstract][Full Text] [Related]
19. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
20. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
